Join Now

Cannabis Rescheduling Explained: What We Know, What We Don’t, and What’s Next

Last week, President Trump made history when he signed an executive order (EO) directing the Attorney General to expedite the process of reclassifying cannabis to Schedule III and removing barriers to research to “increase medical marijuana and CBD research to better inform patients and doctors.” 

There’s no disputing that this is a game-changing moment for the cannabis industry and how the plant is viewed writ-large, but there’s still many questions and unknowns. Let’s take a look at some of the most frequently asked questions I’m getting about what’s next and what it all means:

What Did the Cannabis Rescheduling Executive Order Actually Say?

The EO directs the Attorney General to expedite completion of the process of rescheduling marijuana to Schedule III of the Controlled Substance Act (CSA). It also directs the White House Deputy Chief of Staff for Legislative, Political, and Public Affairs to work with the Congress to allow Americans to benefit from access to appropriate full-spectrum CBD products while still restricting the sale of products that pose serious health risks. Additionally, the EO directs the Department of Health and Human Services (HHS) to develop research methods and models utilizing real-world evidence to improve access to hemp-derived cannabinoid products in accordance with Federal law and to inform standards of care.

When Will Cannabis Rescheduling to Schedule III Take Effect?

What This Means for 280E Relief and Cannabis Businesses

The truth is, we really don’t know. There is no deadline, and we know that it will be at least 30 days due to the Administrative Procedure Act (APA). As of publication, the Attorney General has not filed any type of final rule and neither the DEA nor the DOJ has responded to the public comments that were received on the proposed rule in 2024.

We also have to consider litigation that will surely be filed by our opponents. For instance, Smart Approaches to Marijuana (commonly known as Project SAM) had already stated that they plan to file against the Administration (likely on procedural grounds). 

The APA establishes the framework for judicial review of agency actions and while the APA itself does not specify a statute of limitations for general review, the default period for a civil action against the United States is generally six years after the claim first accrues, however, specific statutes for judicial review of certain agency actions may impose shorter deadlines, sometimes requiring a petition to be filed within 30 days after the final agency action. 

In short, we have to wait and see (frustrating, I know!). 

How Cannabis Rescheduling to Schedule III Affects Banking

A move to Schedule III does not solve the cannabis industry’s banking problems completely. Such a move would/will likely result in lower perceived legal risk for banks, more compliance comfort, expanded access to traditional services, and possibly even improve capital markets access; but it would/will not provide safe harbor for cannabis businesses or automatically change FinCEN guidance. That’s why it’s more important now than ever that we continue to advocate for the introduction and passage of bills like the SAFER Banking Act and the CLAIM Act.

NCIA’s Position on Cannabis Rescheduling to Schedule III

NCIA supports President Trump’s decision to officially direct the Attorney General to reclassify cannabis as a Schedule III substance. Medical professionals, patients, and millions of Americans have long understood that cannabis has accepted medical use and does not belong in the same category as the most dangerous controlled substances. By taking this step, the Administration is recognizing the realities of today’s regulated markets and the work states have done to responsibly oversee them.

That said, Schedule III cannot be the final word. NCIA urges policymakers to build on today’s decision by establishing a framework that respects states’ rights, supports responsible operators, and provides clear federal enforcement guidelines in order to provide certainty to the thousands of businesses operating openly and in compliance with state law. NCIA will continue working to ensure that this industry can thrive under policies that are fair, consistent, and reflective of modern realities.

After more than half a century of prohibition, the importance of this moment cannot be understated- but our association knows that this is just the beginning of a new day for cannabis. As we close out the year, NCIA is thankful to our members for their support and urges those of you who aren’t members to join today or make a donation. Together, we’ll continue to move this industry forward and ensure that progress continues in Washington, DC and beyond. 

Wishing you and yours a wonderful holiday season and happy new year!

Turning Advocacy Wins into Operator Wins

The word “advocacy” is a loaded term. It evokes different emotions in different people. However, in the cannabis industry, it’s a case of goose and gander, as a win for advocacy is a win for operators as well — with policy wins ultimately translating into financial benefits for operators. Thus, it would stand to reason that whenever possible, operators should lend their support to the side of advocacy. In this article, we’ll explore how the two can work together to their mutual benefit.

From Bill Passage to Bank Balance

Due to its quasi-legal status, every positive legislative change can be a massive boon for the cannabis industry. As many are aware, the industry can often operate on a cash-only basis due to federal restrictions. Thus, something like the SAFER Banking Act, which advocates have been pushing for, can be highly beneficial to the industry.

To recap: this act would help provide federal protection to financial institutions, including preventing the depository institution from being penalized for providing banking services to a state-sanctioned cannabis business. Further, the Act prohibits a federal banking service from requesting or requiring a depository institution to cancel a deposit account.

While this act is still waiting to be passed by the Senate, it could represent a significant step forward for the industry by offering essential banking services such as loans, credit lines, and cash management services, such as armored deposit services.

Another big issue for cannabis advocacy is rescheduling. Going from a Schedule I narcotic to a Schedule III narcotic would also open many doors for the industry. One of the most significant advantages of this shift would be the elimination of IRC 280E, which restricts what operators can deduct under the tax code. Unshackled from this prohibitive tax code, operators would have a wealth of items they could deduct, such as wages, rent, utilities, insurance, marketing, and administrative costs.

The benefits of rescheduling wouldn’t stop there. This shift could also herald more research and development opportunities for cannabis, as there would be a greater legal recognition of the plant’s medicinal value.

TL;DR: Advocacy could help operators in many ways; here are but a few examples:

  • The SAFER Banking Act would provide federal protections, allowing banks to safely offer essential services, such as checking accounts, loans, and cash management, to state-legal cannabis businesses. This would reduce cash-only risks and improve industry stability.
  • Rescheduling cannabis to Schedule III would eliminate the restrictive tax code 280E, enabling cannabis businesses to deduct regular business expenses and promoting more research, development, and legal recognition of cannabis’s medical value.

Now, let’s discuss how the industry is already working together to be most effective for everyone.

Coalition Building

Fortunately for the cannabis industry, supporters are passionate and proactive. We can examine several examples of how the industry has leveraged partnerships across different segments to the benefit of everyone.

California NORML – (CA NORML)

The oldest chapter of NORML, established in 1972, the National Organization for the Reform of Marijuana Laws — California chapter continues its legacy from the Compassionate Use Act of 1996 to the recent passage of AB 564, a tax-reducing policy.

California NORML unites the cannabis industry by coordinating lobbying, publishing resources, and building a business directory — acting as a bridge between consumers, legislators, and cannabis businesses to promote equitable laws and industry cohesion.

The Minority Cannabis Business Association (MCBA)

Favoring a grassroots approach, the MCBA seeks, in their words:

“To create equal access for cannabis businesses and economically empower communities of color through policy, programming, and outreach initiatives to achieve equity for the communities most impacted by the War on Drugs.”

Through advocacy and events, the MCBA creates partnerships through many industry segments (retail, cultivation, etc.) for maximum impact.

Besides working together, let’s explore how we can utilize one state’s win as a model for others.

National Cannabis Industry Association (NCIA)

NCIA brings together various players in the cannabis industry by providing national advocacy, policy coordination, education, networking, and a member directory across all verticals — ensuring businesses and stakeholders speak with one informed, powerful voice.

Scaling Local Success 

We can look to states such as California, Oregon, and Washington as (limited) success stories. These states have passed legislation enabling their governors to enter into interstate agreements, allowing border-transversing sales of cannabis between states where it is legal. This enables operators to reach far-flung markets beyond their home state. We see how these states follow each other’s lead while also working collaboratively to secure the best return on investment, although full-scale interstate commerce remains limited pending federal changes.

We can also turn back the clock nearly thirty years from today to when California passed the Compassionate Use Act of 1996. Other states would follow California’s model, and by 2023, 37 states had medical marijuana laws.

Or we can turn to Colorado and Washington, rewinding the clock not quite as far to 2012, when the states legalized recreational cannabis use. This would also serve as a model for other states, and by 2023, 19 states had followed Colorado’s example.

It goes without saying that when one state makes progress for cannabis reform and has quantifiable results, other states are likely to follow suit.

Conclusion

There is no cannabis industry without advocacy. Every step advocacy makes, operators are in lockstep with it. Fortunately, as competitive as the industry is, groups like the National Cannabis Industry Association are arduously working for legislative changes that benefit many in the industry. At the same time, we have other organizations like the Minority Cannabis Business Association toiling to help specific groups that have been historically disadvantaged. However, when these minority groups benefit, everyone benefits — as these social equity initiatives support whole communities by providing jobs and using tax revenue for mental health support, legal services, and other community reinvestment programs.

And speaking of tax revenue, when one state’s cannabis laws are effective — whether medical or recreational — it’s easier to get the ball rolling on similar laws in other states.

Committee Insights: Rescheduled Realities – Redefining Cannabis Manufacturing

Access the full recording of our insightful webinar, “Rescheduled Realities,” and explore the transformative impact of cannabis rescheduling to Schedule III on the manufacturing sector.

In this fifth installment of NCIA’s #IndustryEssentials multi-part webinar series, our expert Cannabis Manufacturing Committee delves into the major shifts and implications following the rescheduling of cannabis. This session provides invaluable insights and practical guidance to help your business adapt and excel in the evolving landscape.

Learning Objectives:

  • Future of Manufacturing Post-Rescheduling: Understand the anticipated changes and their impact on the industry.
  • GMP and Regulatory Requirements: Navigate the updated Good Manufacturing Practices and regulatory standards.
  • Focus on Extracts and Concentrates: Gain insights into the production and regulation of cannabis extracts and concentrates.
  • Impact of Big Pharma: Explore how the pharmaceutical industry’s involvement might influence manufacturing.
  • Best Practices for Non-Pharmaceutical Quality: Learn strategies to maintain high-quality standards in a non-pharmaceutical context.

Hear from Our Expert Panelists:

This session is essential for cannabis manufacturers looking to navigate the upcoming changes, ensure compliance, and maintain high-quality production standards. Join us to stay informed and prepared for the future of cannabis manufacturing.

Why Watch?
Gain critical knowledge and practical tools to adapt to regulatory changes, enhance your manufacturing practices, and remain competitive in the market.

Watch Now to equip yourself with the insights needed to thrive in the new cannabis manufacturing landscape!

Committee Insights: Redefining Cannabis Marketing – Strategies for Success in a Schedule III Landscape

Access the full recording of our insightful webinar, “Redefining Cannabis Marketing,” and discover how to navigate the evolving landscape of cannabis marketing and advertising post-rescheduling.

In this pivotal episode, the Marketing & Advertising Committee collaborates with the State Regulations Committee to explore the potential impact of cannabis transitioning to Schedule III. This session addresses the new opportunities and challenges for businesses in the cannabis space, providing you with essential strategies for success.

What You’ll Learn:

  • New Regulatory Guidelines: Get up-to-date on the latest regulatory changes and their effects on cannabis marketing.
  • Innovative Marketing Strategies: Explore cutting-edge approaches to effectively engage your audience in a more flexible regulatory environment.
  • Compliance Best Practices: Understand how to stay compliant with evolving standards while optimizing your marketing efforts.

Hear from Our Expert Panelists:

  • Colton Griffin, CEO of Flourish Software
  • Valerie Taylor, Vice President (National Cannabis Practice Leader) at The Liberty Company Insurance Brokers
  • Joseph Smith, Partner at Thompson Hine
  • Patrick Toste, Co-Founder & Creative Director of HIGHOPES Design
  • Jen Lamboy, Director of Strategy at Hybrid Marketing

This webinar builds on our series examining tax implications, research, safety, and facility design in the new Schedule III era. Gain invaluable insights from industry leaders to ensure your business thrives amidst these regulatory shifts.

These industry leaders will share their expertise, providing invaluable insights to ensure your business thrives amidst regulatory changes.

Why Watch?
Stay ahead in the rapidly changing cannabis market with expert guidance on regulatory compliance and innovative marketing strategies.

Watch Now to equip yourself with the knowledge needed to excel in the new cannabis marketing landscape!

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.